Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Understanding Immunologic Complications of Measles

Ruth Jessen Hickman, MD  |  Issue: August 2025  |  August 6, 2025

Dr. Calabrese

Cassandra Calabrese, DO, a double-boarded rheumatologist and infectious disease specialist who is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine, notes that this second dose is not considered a booster and is not necessary for inducing immunity, but it does increase the overall effectiveness from 93% to 97%.

Thanks to these changes and effective public health efforts, the disease was considered eliminated in the U.S. in 2000—defined as having no locally transmitted virus within a 12-month period, although isolated cases may still occur in people traveling to places where the virus remains endemic.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recent U.S. Outbreaks

Despite these gains, global case numbers rose in the 2010s. In 2019, measles’ elimination status in the U.S. was threatened, with almost 1,300 documented measles cases in a large outbreak in New York and additional cases in another 30 states.1

In a webinar, Daniel Salmon, PhD, MPH, speculated that the U.S. probably would have lost its elimination status in 2020 had not the COVID-19 pandemic intervened, causing global decreases in case numbers due to measures to decrease the spread of SARS-CoV-2. Dr. Salmon is director of the Institute for Vaccine Safety at the Johns Hopkins Bloomberg School of Public Health, Baltimore.10

Dr. Salmon

The pandemic disrupted regular measles immunization schedules in many countries.1,11 And the incidence of measles cases has continued to rise since, with particularly large outbreaks in parts of Africa, Asia and Europe.

As of mid-July, the Centers for Disease Control and Prevention (CDC) reports that more than more than 1,300 cases of measles have occurred in 40 U.S. jurisdictions in 2025, leading to hospitalization in 13% of patients (164 individuals) and three deaths. Notably, 96% of cases occurred in people who were unvaccinated or had an unknown vaccination status.12

“Should transmission exceed 12 months, we may lose our measles elimination status,” says Dr. Moss.

“Outbreaks of a vaccine-preventable illness like this are always unfortunate and disappointing,” says Dr. Calabrese, “but I think the current rise in cases is quite disconcerting.”

In the U.S., vaccination rates widely vary by state (below 80% in Idaho to 98% in West Virginia) and county, with even smaller areas of geographic clustering. More than 550 of the current reported cases are from west Texas, centered on a close-knit, unvaccinated Mennonite community.13 Dr. Calabrese points out that vaccination rates in these areas are well below the roughly 95% vaccination threshold necessary to prevent spreading.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGuidance Tagged with:BiologicsImmunityimmunocompromisedimmunosuppressioninfectious diseaselive vaccineMeaslesMMRoutbreakspublic healthvaccinationvaccine hesitancy

Related Articles
    phichet chaiyabin / shutterstock.com

    Measles Is Back. How Does This Affect Patients with Rheumatic Disease?

    August 16, 2019

    Despite the presence of a highly effective vaccine, measles (rubeola) is still an important problem worldwide, one that has reemerged in some areas of the world where it had previously been almost eradicated. Rheumatology patients may have questions about whether they are sufficiently protected. Here we discuss key considerations for rheumatologists in light of recent…

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

    Space & Other Races

    October 19, 2020

    On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics. I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEThis group of scientists met to discuss…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences